Available in GitHub, Code Brings New Tools to Research Studies
RESEARCH TRIANGLE PARK, N.C. – November 9, 2015 – Quintiles, the world’s largest biopharma services provider, has announced its contribution of enhancements to the ResearchKit framework which was designed by Apple to make it easy for researchers to gather data more frequently and more accurately from research participants using iPhone apps.
ResearchKit enables participants to easily complete tasks or submit surveys right from an app and delivers a simple way to present participants with an interactive informed consent process. Quintiles contributed enhancements to the ResearchKit framework to provide developers with extensions that support additional capabilities which, in turn, will allow them to create more sophisticated application experiences. Quintiles plans to use these enhancements to develop patient engagement tools for ResearchKit-based apps.
As the number one ranked late-phase research organization, Quintiles’ technology and digital health experts are actively integrating and further enhancing ResearchKit as a tool for its customers' research studies to deliver a superior patient and caregiver experience.
“Quintiles has a deep understanding of patient behavior, having conducted more than 400 direct-to-patient programs since 2008,” said Quintiles President of Technology and Solutions Richard Thomas. “We embraced those principles in our development of enhancements to the ResearchKit framework.”
“We believe Quintiles’ contribution of these enhancements is a significant advancement within the clinical research industry,” Thomas continued. “They will not only improve the apps Quintiles develops for its own use, but can enhance all apps developed using ResearchKit. Working with the ResearchKit framework gives us a profound understanding of its capabilities and how best to optimize it in the apps we develop for our clinical research customers.”
For more information on Quintiles’ contributions to ResearchKit, please visit our website at http://www.quintiles.com/researchapps.
About Quintiles
Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.